All About Multiple Sclerosis

More MS news articles for May 2004

Cell-based remyelinating therapies in multiple sclerosis: evidence from experimental studies

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15167057

Curr Opin Neurol. 2004 Jun;17(3):247-55
Pluchino S, Furlan R, Martino G.
Neuroimmunology Unit - Department of Biotechnology (DIBIT) and Department of Neurology and Neurophysiology, San Raffaele Scientific Institute, Milan, Italy.

PURPOSE OF REVIEW:

Spontaneous remyelination occurs in the central nervous system of patients with multiple sclerosis.

However, this process is not robust enough to promote a functional and stable recovery of the myelin architecture.

The development of cell-based therapies, aimed at promoting multifocal remyelination, is therefore foreseen.

RECENT FINDINGS:

Several experimental cell-based strategies aimed at replacing damaged myelin-forming cells have been developed in the last few years.

However, most of these therapeutic approaches - although consistently able to form new myelin sheaths at the transplantation site - are unfeasible owing to the mutifocality of the demyelinating process in multiple sclerosis patients and the inability to grow and produce large numbers of differentiated myelin-forming cells in vitro.

Stem cell-based therapies that partially overcome these limitations have been proposed recently.

SUMMARY:

Stem cell-based remyelinating therapies can be considered a plausible alternative strategy in immune-mediated demyelinating disorders.

However, before any potential applications in patients with multiple sclerosis can be envisaged, it is necessary to confront the following preliminary, and still unsolved, questions:

(1) the ideal stem cell source for transplantation;

(2) the most appropriate route of stem cell administration; and, last but not least,

(3) the best approach for achieving an appropriate, functional and long-lasting integration of transplanted stem cells into the host tissue.